Given our previous finding that splicing factor mutations confer sensitivity to ATR inhibition [32], we examined the response of SRSF2-mutant AML samples to ATR inhibitors and its downstream effector kinases, CHK1 and WEE1. The gene discussed is SLU7; the disease is acute myeloid leukemia.